Scinai's H1 2026: $3.1M in CDMO Orders, $650K in U.S. Program Advances, and a $6.4M Non-Cash Gain
SCNI sits 29% above its 52-week low of $2.147 on elevated volume (2.1× avg).
Summary
Scinai's H1 2026 filing shows growing CDMO momentum with $3.1M in committed orders and a new U.S. clinical manufacturing program, but the underlying business still burns cash and the reported profit is entirely a non-cash acquisition gain.
Key Events · Earnings and Guidance · SCNI
-
H1 2026 Net Income Driven by Non-Cash Gain
Net income of $1.6M was entirely attributable to a $6.4M bargain purchase gain from the Recipharm Israel acquisition; underlying operating loss was $4.6M.
-
CDMO Committed Orders Reach $3.1M
Committed Customer Orders totaled approximately $3.1M as of August 16, 2026, with approximately $2.1M already invoiced.
-
U.S. Clinical Manufacturing Program Advances
Expanded U.S. clinical manufacturing and CMC program received approximately $650K in cash payments and advances; definitive agreement still under negotiation.
-
Cash Position and Burn Rate
Cash, cash equivalents and restricted cash totaled $2.9M at June 30, 2026, against $3.9M in net cash used in operating activities during H1 2026.
Analysis · SCNI · Life Sciences
Scinai's first-half 2026 results reveal a company in transition. The CDMO business is gaining commercial traction, with $3.1 million in committed customer orders and a new U.S. clinical manufacturing program that has already brought in $650,000 in cash advances. Yet the underlying operation still lost $4.6 million. The reported $1.6 million net profit is entirely a non-cash bargain purchase gain from the Recipharm Israel acquisition—not operating income. With a cash position of $2.9 million at June 30, 2026, against a $3.9 million operating cash burn, the company's need for external funding remains acute. Adding to the challenges, the revised FENG grant application was never submitted due to a consultant's administrative error, a setback for the PC111 program's non-dilutive funding path.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 29.6% of the 2920 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $2.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.15 to $16.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.